LOUISVILLE, Colo., March 20, 2026 /CNW/ - (TSX: CWEB) (OTCQB: CWBHF) Charlotte's Web Holdings, Inc. (the "Company" or "Charlotte's Web"), a botanical wellness innovation company and the market leader in cannabidiol ("CBD") hemp extract wellness products, extends its sincere appreciation to the Centers for Medicare & Medicaid Services (CMS) and the Administration for their leadership in advancing structured access to eligible full‑spectrum hemp products through current CMS Innovation Center models, as reflected in CMS's new Substance Access Beneficiary Engagement Incentive (BEI) guidance pages. Under the BEI, CMS has defined eligible hemp products to include orally administered products containing up to 3 mg per serving of tetrahydrocannabinols, a threshold that accommodates non-intoxicating full-spectrum hemp-derived CBD products. This forward‑looking framework supports patient‑provider discussions around eligible hemp products, reinforcing science‑driven policymaking that prioritizes consumer safety and product quality.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Charlotte's Web Welcomes New CMS Guidance, Advancing Access to Eligible Full‑Spectrum Hemp Products
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
